Alzheimer’s Disease (AD), the most common neurodegenerative disease, is underdiagnosed and more prominent in underrepresented groups. We performed semi-supervised positive unlabeled learning (SSPUL) coupled with racial bias mitigation for equitable prediction of undiagnosed AD…
Continue Reading
Artificial intelligence models analyzing speech show remarkable promise for identifying cognitive decline, achieving performance comparable to clinical assessments. However, their “black box” nature poses significant barriers to clinical adoption, as healthcare professionals require transparent…
Continue Reading
What You Should Know:
– Philips and Cortechs.ai are strengthening their collaboration to integrate AI-enabled quantitative neuroimaging analytics directly into Philips’ MR systems.
The integration provides clinicians with faster, more objective, and reproducible insights into brain…
Continue Reading
Generative artificial intelligence is revolutionizing digital twin development, enabling virtual patient representations that predict health trajectories, with large language models (LLMs) showcasing untapped clinical forecasting potential. We developed the Digital Twin—Generative Pretrained Transformer (DT-GPT),…
Continue Reading
What You Should Know:
– GE HealthCare has announced its agreement to acquire icometrix, a company specializing in AI-powered brain imaging analysis.
– The acquisition is a strategic move to address the growing demand for MRI…
Continue Reading
Large language models (LLMs) have shown promising capabilities across diverse domains, yet their application to complex clinical prediction tasks remains limited. In this study, we present CARE-AD (Collaborative Analysis and Risk Evaluation for Alzheimer’s…
Continue Reading
Dr. Richard S. Isaacson, Neurologist at The Institute for Neurodegenerative Diseases (IND)
Dr. Kellyann Niotis M.D. Neurologist at The Institute for Neurodegenerative Diseases (IND)
Hundreds of millions of people worldwide live with a high risk of…
Continue Reading
Elisabeth Thijssen, PhD, Chief Scientific Officer of Neurogen Biomarking.
What You Should Know:
– Advancements in accelerating early Alzheimer’s disease (AD) screening and access to care, proven from three diverse community pilot initiatives, were presented today…
Continue Reading
Alzheimer’s Disease and Related Dementias (ADRD) pose a major public health challenge, with a critical need for accurate and scalable tools for detecting cognitive impairment (CI). Readily available electronic health records (EHRs) contain valuable…
Continue Reading
As digital biomarkers gain traction in Alzheimer’s disease (AD) diagnosis, understanding recent advancements is crucial. This review conducts a bibliometric analysis of 431 studies from five online databases: Web of Science, PubMed, Embase, IEEE…
Continue Reading
